ARV-110: an oral androgen receptor PROTAC® degrader for prostate cancer

Read More »

ARV-471, an oral estrogen receptor PROTAC® protein degrader for breast cancer

Read More »

An oral androgen receptor PROTAC® degrader for prostate cancer

Read More »

Identification of Oral Estrogen Receptor PROTAC® Degraders for Breast Cancer

Read More »

The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study

Read More »

Lessons in PROTAC® Design from Selective Degradation with a Promiscuous Warhead

Read More »

BET protein proteolysis targeting chimera (PROTAC®) exerts potent lethal activity against mantle cell lymphoma cells

Read More »

Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs®) of TANK-Binding Kinase 1

Read More »

An Oral Androgen Receptor PROTAC® Degrader for Prostate Cancer

Read More »

An Oral Androgen Receptor PROTAC® Degrader for Prostate Cancer

Read More »